2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6267 Comparison of racial differences in five-year survival among patients with diffuse large B-cell lymphoma in the pre-polatuzumab and polatuzumab eras using real world data

Chinenye Okafor, MD, MPH, FNU Zeesha, MD2, Nikita Kumari, MD3, Rami Tfayli, MD4, Wael Ghalayini, MD, MBA, MS FACP5
1 Medical University of South Carolina, Florence, South Carolina, United States
2 Medical University of South Carolina, Florence, South Carolina, United States
3 Medical University of South Carolina, Florence, South Carolina, United States
4 Medical University of South Carolina, Florence, South Carolina, United States
5 Medical University of South Carolina, Florence, South Carolina, United States

INTRODUCTION

Population-based studies have shown continued increase mortality trends for diffuse large B-cell lymphoma (DLBCL) since the early 2010s, with specifically vulnerable subgroups identified as older adults, Black and Asian DLBCL patients. This disproportionate worse survival outcomes have been attributed to receipt of therapy, older age at diagnosis and access to care. With recent advances in DLBCL therapy such as the approval of Polatuzumab in 2019 and its expansion to first-line therapy for advanced disease, studies have shown an overall improvement in DLBCL survival. However, more information is needed to evaluate if survival disparities have persisted with therapy advances.

Objective: To evaluate the differences in 5-year overall survival between Black and White DLBCL patients, and Asian and White DLBCL patients in the pre-polatuzumab and polatuzumab eras.

METHODS

This was a retrospective study utilizing data from the US Collaborative Network of TriNetX global health research database. We identified patients who have a diagnosis of DLBCL with the pre-polatuzumab era defined as January 2014 to December 2019, and polatuzumab era defined as January 2020 to December 2025. We then created cohorts for Black, White and Asian patients within each predefined era. Primary outcome was 5-year overall survival.

Using propensity-score matching (PSM) within each era, individual comparison cohorts (i.e. Black vs White, and Asian vs White) were balanced by age at diagnosis, lactate dehydrogenase level (using categories of <200U/l, 200-400U/l, >400U/l) and use of polatuzumab. Kaplan Meier survival curves and Cox proportional hazard ratio were used to evaluate 5-year survival by comparing predefined racial groups within each era.

Before PSM, 35,263 White, 3,944 Black and 1,527 Asian patients were identified in the pre-polatuzumab era while 53,298 White, 6,030 Black and 2,861 Asian patients were identified in the polatuzumab era.

RESULTS

Results after PSM are reported.

In the pre-polatuzumab era, there were 7,880 Black and White patients (3,940 each) with a median age of 57 (IQR of 23) years, and 3,054 Asian and White patients (1,527 each) with a median age of 66 (IQR of 22) years. Black DLBCL patients had significantly lower 5-year overall survival (74.2% vs 76.7%; p=0.01) compared to White DLBCL patients (HR 1.14, 95% CI 1.04-1.25). No survival differences were noted when Asian patients were compared to White patients (72.2% vs 72.6%; p=0.54. HR 1.05, 95% CI 0.91-1.21).

In the polatuzumab era, 12,022 Black and White DLBCL patients (6,011 each) with a median age of 61 (IQR of 24) years, and 5,102 Asian and White DLBCL patients (2,551 each) with a median age of 68 (IQR of 20) years were included. Black patients had significantly lower 5-year overall survival (71.5% vs 73.5%, p=0.04) compared to their White counterparts (HR 1.09, 95% CI 1.01-1.18) while no survival differences were observed when Asian patients were compared to White patients (71.4% vs 69.5%; p=0.77. HR 0.98, 95% CI 0.87-1.11).

CONCLUSION

Black DLBCL patients had worse 5-year survival outcomes compared to their propensity-matched White counterparts and this disparity persisted in the polatuzumab era despite advances in DLBCL therapy. Although DLBCL therapy continues to advance, at-risk populations such as Black patients appear to not have captured these benefits. Prior studies have linked lower overall DLBCL survival to later disease stage at presentation attributing this to socioeconomic factors, insurance status, and access to care which disproportionately affect specific patient subgroups despite advances in treatment options. Although this study does not take disease stage into account, it did account for use of polatuzumab which is mostly used in advanced or bulky diseases. Future research is needed to evaluate potential patient-level factors such as social determinants of health that may be driving these survival differences.

Chinenye Okafor, MD, MPH: No relevant conflicts of interest to declare.